These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37469041)

  • 21. Low Dose Buprenorphine Induction With Full Agonist Overlap in Hospitalized Patients With Opioid Use Disorder: A Retrospective Cohort Study.
    Bhatraju EP; Klein JW; Hall AN; Chen DR; Iles-Shih M; Tsui JI; Merrill JO
    J Addict Med; 2022 Jul-Aug 01; 16(4):461-465. PubMed ID: 34954743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder.
    Leech AA; McNeer E; Roberts AW; Dusetzina SB; Lai P; Morgan JR; Patrick SW
    JAMA Intern Med; 2023 Sep; 183(9):1023-1026. PubMed ID: 37548972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Buprenorphine utilization among all Washington State residents' based upon prescription monitoring program data - Characteristics associated with two measures of retention and patterns of care over time.
    Banta-Green CJ; Hansen RN; Ossiander EM; Wasserman CR; Merrill JO
    J Subst Abuse Treat; 2021 Aug; 127():108446. PubMed ID: 34049724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
    Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
    Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
    Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
    Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
    Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
    Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data.
    Hjelmström P; Banke Nordbeck E; Tiberg F
    Drug Dev Ind Pharm; 2020 Jan; 46(1):1-7. PubMed ID: 31914818
    [No Abstract]   [Full Text] [Related]  

  • 30. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.
    Williams AR; Samples H; Crystal S; Olfson M
    Am J Psychiatry; 2020 Feb; 177(2):117-124. PubMed ID: 31786933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nine-year substance use treatment outcomes with buprenorphine for opioid use disorder in a federally qualified health center.
    Haddad M; Coman E; Bifulco L
    Drug Alcohol Depend; 2024 Apr; 257():111252. PubMed ID: 38484404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
    Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
    JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Use of Once-monthly Injectable Buprenorphine for the Treatment of Opioid Use Disorder in Postpartum Women: A Case Series.
    Shadowen C; Moeller FG; Martin CE
    J Addict Med; 2021 Jul-Aug 01; 15(4):292-296. PubMed ID: 34397780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to buprenorphine: An analysis of prescription drug monitoring program data.
    Pizzicato LN; Hom JK; Sun M; Johnson CC; Viner KM
    Drug Alcohol Depend; 2020 Nov; 216():108317. PubMed ID: 33035714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
    Bastien G; McAnulty C; Ledjiar O; Socias ME; Le Foll B; Lim R; Hassan AN; Brissette S; Marsan S; Talbot A; Jutras-Aswad D;
    Can J Psychiatry; 2023 Aug; 68(8):572-585. PubMed ID: 36519188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy Dose Mediates the Relationship Between Buprenorphine/Naloxone and Opioid Treatment Outcomes in Youth Receiving Medication for Opioid Use Disorder Treatment.
    Hammond CJ; Kady A; Park G; Vidal C; Wenzel K; Fishman M
    J Addict Med; 2022 Mar-Apr 01; 16(2):e97-e104. PubMed ID: 33973923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-buprenorphine opioid utilization among patients using buprenorphine.
    Daubresse M; Saloner B; Pollack HA; Alexander GC
    Addiction; 2017 Jun; 112(6):1045-1053. PubMed ID: 28107580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.
    Schuman-Olivier Z; Hoeppner BB; Weiss RD; Borodovsky J; Shaffer HJ; Albanese MJ
    Drug Alcohol Depend; 2013 Oct; 132(3):580-6. PubMed ID: 23688843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.
    Bach P; Bawa M; Grant C; Milloy MJ; Hayashi K
    Int J Drug Policy; 2022 Mar; 101():103545. PubMed ID: 34875527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A; Petrakis I; Rosenheck R
    Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.